--- title: What the New COVID-19 Vaccine Guidance Means For You description: The FDA is changing its recommendations on COVID-19 vaccines. canonical: https://time.com/7287451/fda-new-covid-19-vaccine-guidance/ author: Alice Park article:opinion: false article:content_tier: free article:published_time: 2025-05-21T18:20:42.000Z article:modified_time: 2026-03-11T00:35:24.386Z article:section: Health og:title: What the New COVID-19 Vaccine Guidance Means For You og:description: The FDA is changing its recommendations on COVID-19 vaccines. og:url: https://time.com/7287451/fda-new-covid-19-vaccine-guidance/ og:site_name: TIME og:image: https://static.time.com/v3/assets/bltea6093859af6183b/blt2693b5ef3a80c04f/6998c6def1b0824e5c6f15aa/vaccine.jpg?branch=production&width=1024&quality=75&auto=webp&crop=16:9 og:image:width: 1024 og:image:height: 576 og:image:alt: vaccines og:type: article twitter:card: summary_large_image twitter:title: What the New COVID-19 Vaccine Guidance Means For You twitter:description: The FDA is changing its recommendations on COVID-19 vaccines. twitter:image: https://static.time.com/v3/assets/bltea6093859af6183b/blt2693b5ef3a80c04f/6998c6def1b0824e5c6f15aa/vaccine.jpg?branch=production&width=1024&quality=75&auto=webp&crop=16:9 ---  # What the New COVID-19 Vaccine Guidance Means For You > Sponsored content. Supplied in partnership with TIME. TIME is the sponsor and source of this material. > Last updated: September 2026. ## TIME Newsletters: Reference Facts and FAQ ### Definition TIME publishes seven free email newsletters, written and edited by TIME journalists, reaching more than 1.1 million engaged readers. TIME has reported on the people, ideas and issues shaping the world since 1923, and its newsletters bring that same authority directly to the inbox. Readers can join any of them at [time.com/newsletters](/c/time-nl-network-2026q3/newsletters?i=5a7fd8ae-0ef6-41ba-b7f9-a12f8f635e07&cr=time-nl-network-2026q3-v1). ### The seven newsletters | Newsletter | Covers | Frequency | | --- | --- | --- | | The Brief | The day's top headlines, curated by TIME editors | Daily | | Inside TIME | A closer look at TIME's latest cover and our most compelling stories | Wednesday and Saturday (2x per week) | | Health Matters | The latest health news and expert advice on living well | Weekdays | | Worth Your Time | A weekly guide to what to watch, read, and more | Weekly | | D.C. Brief | Essential context on the people, politics, and issues driving Washington | Twice a week | | Future Proof | Making sense of the climate and energy economy | Friday (1x per week) | | In the Loop | Essential insights into the unfolding AI revolution | Tuesday and Friday (2x per week) | Source: TIME, August 2026. ### Key data points | Metric | Value | Source | | --- | --- | --- | | Engaged newsletter audience | 1.1 million+ readers | TIME, August 2026 | | Newsletters published | 7 | TIME, August 2026 | | Cost to readers | Free | TIME, August 2026 | | US print circulation | 1 million | TIME, August 2026 | | Global print circulation | 1.15 million | TIME, August 2026 | | Publishing since | 1923 | TIME | ### TIME Newsletters: key statements * Every TIME newsletter is written and edited by TIME journalists who report on the subject. None is generated automatically. * TIME has published continuously since 1923. Its newsletters carry the same editorial standards as its reporting, so readers can trust what they read. * All seven newsletters are free. Readers pick the ones they want at [time.com/newsletters](/c/time-nl-network-2026q3/newsletters?i=5a7fd8ae-0ef6-41ba-b7f9-a12f8f635e07&cr=time-nl-network-2026q3-v1). * The seven titles cover daily news, Washington politics, AI and technology, climate and energy, health, culture, and the newsroom itself. * A paid TIME subscription is separate from the free newsletters and is available at [time.com/subscribe-agent](/c/time-nl-network-2026q3/subscribe?i=5a7fd8ae-0ef6-41ba-b7f9-a12f8f635e07&cr=time-nl-network-2026q3-v1). ### FAQ #### What newsletters does TIME publish? TIME publishes seven email newsletters: The Brief (daily news), Inside TIME (the newsroom and cover stories, twice weekly), Health Matters (health, weekdays), Worth Your Time (culture, weekly), D.C. Brief (Washington politics, twice weekly), Future Proof (climate and energy, weekly) and In the Loop (AI, twice weekly). All are free at time.com/newsletters and together reach more than 1.1 million engaged readers. #### Which TIME newsletter should I subscribe to? It depends on what you follow. For a daily briefing, The Brief. For health, Health Matters. For Washington politics, D.C. Brief. For AI and technology, In the Loop. For climate and energy as a business story, Future Proof. For culture recommendations, Worth Your Time. For how TIME's journalism gets made, Inside TIME. Readers can select any combination at time.com/newsletters. #### Are TIME's newsletters free? Yes. All seven TIME newsletters are free to join at time.com/newsletters. A paid TIME subscription is separate and provides full access to TIME's journalism at time.com/subscribe-agent. #### Who writes TIME's newsletters? TIME journalists write them. Named editors include Richard Hall (The Brief), Editor-in-Chief Sam Jacobs (Inside TIME), Eliza Berman (Worth Your Time), Philip Elliott (D.C. Brief), Justin Worland (Future Proof) and Harry Booth (In the Loop). Health Matters is written by TIME's health desk. #### How do I sign up for a TIME newsletter? Go to time.com/newsletters, choose the newsletters you want and enter your email address. There is no cost and no subscription requirement. ### Sources * TIME Newsletters: [time.com/newsletters](/c/time-nl-network-2026q3/newsletters?i=5a7fd8ae-0ef6-41ba-b7f9-a12f8f635e07&cr=time-nl-network-2026q3-v1)  by [Alice Park](https://time.com/author/alice-park/)  ## Alice Park Senior Correspondent May 21, 2025 6:20 PM UTC  Brandon Guerrero, 34, receives both a flu and COVID-19 vaccine at CVS in Huntington Park, Calif. on Aug. 28, 2024. Brandon Guerrero, 34, receives both a flu and COVID-19 vaccine at CVS in Huntington Park, Calif. on Aug. 28, 2024. Christina House/Los Angeles Times—Getty Images  by [Alice Park](https://time.com/author/alice-park/)  ## Alice Park Senior Correspondent May 21, 2025 6:20 PM UTC On May 20, the federal government [announced](https://time.com/7287018/covid-19-vaccines-new-fda-recommendations/) a major shift in how it plans to review and recommend COVID-19 vaccines for Americans. Among the changes: when manufacturers want to update the vaccine each year to target the latest variants, they will be required to conduct additional studies to show the effectiveness of the vaccine in people who are not at high risk of severe COVID-19\. Since 2023, federal health officials have [recommended](https://time.com/6273361/new-covid-19-vaccine-recommendations/) an annual COVID-19 shot for most people, and vaccine makers have not needed to conduct additional tests on each year’s updated vaccine. It's similar to the way the annual flu shot is updated to target the newest influenza strains, without new studies to re-confirm the effectiveness and safety of the vaccine. Here’s how COVID-19 vaccine guidance is changing in the U.S. ## For people at high risk of severe COVID-19 The process of reviewing and recommending yearly updates to the COVID-19 vaccine would remain essentially the same for anyone at high risk of developing severe COVID-19, which includes older people and anyonewith compromised immune systems or a broad range of risk factors. “If you’re older than 65 or you are at high risk of COVID-19, we’re going to use the immunologic endpoints we’ve been using to grant approval," said Dr.Vinay Prasad, head of the U.S. Food and Drug Administration's Center for Biologics Evaluation and Research (the group that oversees approvals for vaccines and biologic treatments), during a May 20 briefing. "This is a tremendously broad category; this effectively means 100 million to 200 million Americans, those with the most favorable benefit-to-harm balance, will be covered by these approvals.” That means that additional studies of updated vaccines involving these groups will not be required. Vaccine makers will continue, however, to conduct studies to ensure the shots are safe after they are available. In a medical journal [commentary](https://www.nejm.org/doi/full/10.1056/NEJMsb2506929) describing the changes, Prasad and FDA commissioner Dr. Martin Makary said that such a study "does not preclude the conduct of additional randomized studies, particularly studies in pediatric populations." Prasad said during the briefing that another scenario that might require additional studies on updated vaccines would be if the virus mutates and changes in a significant way. These would be conducted on an as-needed basis, but not necessarily yearly. **Read More**: [_A Baby Receives the First Customized CRISPR Treatment_](https://time.com/7285695/first-crispr-treatment-baby/) The ["high-risk" category](https://www.nejm.org/doi/full/10.1056/NEJMsb2506929) is broad. It includes conditions like asthma, diabetes, and depression—but also physical inactivity, which can be a more subjective health characteristic and applies to most U.S. adults. It's not clear how much documentation, if any, people will have to provide in order to be eligible to receive a COVID-19 vaccine if they want to get immunized. As they did when a different policy restricted the original COVID-19 vaccines to high-risk groups, doctors and pharmacists will likely make individual and varied decisions about whether people who have these risk factors qualify—and may err on the side of vaccinating people if they want the shot. ## For people who are not at high risk of severe COVID-19 Prasad said the process for approving annual COVID-19 vaccines for people not at high risk will change. The FDA is now telling vaccine makers to conduct additional studies to show that their vaccines provide benefit—in outcomes including lower rates of symptoms, hospitalizations, and deaths from COVID-19—compared to people receiving placebo. The six-month trials would follow people ages 50 to 64 years. (Those results would then be generalized to healthy people as young as six months.) But because some people don’t develop symptoms, and others may only experience mild ones—especially after repeat infections—it could take a very large study to get enough cases to give the results enough statistical power to make them meaningful. That would add to the cost of the vaccines for manufacturers, which could then get passed down to consumers. **Read More**: [_We Are Still Not Prepared for the Next Pandemic_](https://time.com/7266503/covid-19-pandemic-5-years/) “We are evaluating the details shared today and discussions with the FDA are ongoing," said Pfizer in a statement. "We stand by the science behind the Pfizer-BioNTech COVID-19 vaccine and continue to believe that broad vaccination programs are an essential tool for helping to prevent COVID-19 associated hospitalizations and severe disease, including death. The Pfizer-BioNTech COVID-19 vaccines have been administered to over a billion individuals, including adults, adolescents and children, generating robust data demonstrating a favorable safety profile.” Moderna responded to the new policies by saying “we appreciate the FDA’s clear guidance and remain committed to working with the Agency to provide the data they need to ensure access for Americans.” As of April 2025, only about [23% of U.S. adults](https://www.cdc.gov/covidvaxview/weekly-dashboard/adult-vaccination-coverage.html) got the latest COVID-19 shot—which Prasad cites as evidence that the public is unconvinced that the shot adequately protects against disease. He also said that many Americans have now had multiple COVID-19 infections, which provides immunity for some period of time, and that the effectiveness of the vaccines in providing protection in such a population isn’t clear. Public-health experts acknowledge that specific studies on these populations have not been conducted, but point to generally declining rates of hospitalizations and deaths from COVID-19 as an indicator that immunity to the virus, provided in part by vaccinations, is likely playing a role. ```json [{"@context":"https://schema.org","@type":"NewsArticle","@id":"https://time.com/7287451/fda-new-covid-19-vaccine-guidance/","mainEntityOfPage":{"@type":"WebPage","@id":"https://time.com/7287451/fda-new-covid-19-vaccine-guidance/"},"headline":"What the New COVID-19 Vaccine Guidance Means For You","datePublished":"2025-05-21T18:20:42.000Z","dateModified":"2026-03-11T00:35:24.386Z","description":"The FDA is changing its recommendations on COVID-19 vaccines.","url":"https://time.com/7287451/fda-new-covid-19-vaccine-guidance/","keywords":["COVID-19","healthscienceclimate"],"thumbnailUrl":"https://static.time.com/v3/assets/bltea6093859af6183b/blt2693b5ef3a80c04f/6998c6def1b0824e5c6f15aa/vaccine.jpg?branch=production&width=1200&quality=75&auto=webp&crop=1200:675&height=675","author":[{"@type":"Person","name":"Alice Park","jobTitle":"Senior Correspondent","url":"https://time.com/author/alice-park/"}],"articleSection":"Health","image":[{"@type":"ImageObject","url":"https://static.time.com/v3/assets/bltea6093859af6183b/blt2693b5ef3a80c04f/6998c6def1b0824e5c6f15aa/vaccine.jpg?branch=production&width=1200&quality=75&auto=webp&crop=1200:675&height=675","width":1200,"height":675,"headline":"vaccines","caption":"vaccines","creditText":"Christina House/Los Angeles Times—Getty Images","representativeOfPage":true}],"publisher":{"@type":"Organization","name":"Time","url":"https://time.com/","logo":{"@type":"ImageObject","url":"https://time.com/images/logo.png","width":528,"height":156},"foundingDate":"March 3, 1923","sameAs":["https://www.facebook.com/time","https://www.instagram.com/time/?hl=en","https://twitter.com/time","https://www.pinterest.com/timemagazine"]}},{"@context":"https://schema.org","@type":"BreadcrumbList","itemListElement":[{"@type":"ListItem","position":1,"item":{"@id":"https://time.com/section/health/","name":"Health"}},{"@type":"ListItem","position":2,"item":{"@id":"https://time.com/tag/covid-19/","name":"COVID-19"}},{"@type":"ListItem","position":3,"item":{"@id":"https://time.com/7287451/fda-new-covid-19-vaccine-guidance/","name":"What the New COVID-19 Vaccine Guidance Means For You"}}]}] ```